Thus, although C5 inhibitors have improved the prognosis for PNH patients by reducing serious complications, a high proportion of patients exhibit clinical signs of EVH or residual IVH during stable C5 inhibitor therapy [19]. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.